# AstraZeneca Plc expands US R&D and manufacturing footprint with $3.5b investment

- Link: https://www.directorstalkinterviews.com/astrazeneca-plc-expands-us-rd-and-manufacturing-footprint-with-3.5b-investment/4121177058
- Published: 2024-11-12T07:34:54+00:00
- Author: Amilia Stone

**[AstraZeneca Plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
has announced $3.5 billion of capital investment in the United States focused on
expanding the Company’s research and manufacturing footprint by the end of 2026.
This includes $2 billion of new investment creating more than a thousand new, high-
skilled jobs contributing to the growth of the US economy.

AstraZeneca’s expanding footprint in the US includes, among others:

·    A state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts

·    A next generation manufacturing facility for biologics in Maryland

·    Cell therapy manufacturing capacity on the West and East Coasts

·    Specialty manufacturing in Texas

> **Pascal Soriot, Chief Executive Officer, AstraZeneca said**: “_Our multibillion
> dollar investment reflects the attractiveness of the business environment together
> with the quality of talent and innovation capabilities here in the United States.
> By expanding our R&D and manufacturing footprint, we aim to enhance the development
> of cutting-edge therapies and support the United States leadership in healthcare
> innovation_.”

**Delivering growth: Ambition 2030**

These US investments are the first of a series of important steps to help deliver
AstraZeneca’s ambition to achieve $80 billion in Total Revenue by 2030 as set out
in May this year. A key element of our strategy is accelerating the Company’s development
in the United States. The US is AstraZeneca’s largest market, generating 44% of 
its Total Revenue.^(1)

**References**

1.     As at Q3 2024 noted in AstraZeneca Q3 Financial Results. Available at: https://
www.astrazeneca.com/media-centre/press-releases/2024/9m-and-q3-2024-results.html.
Accessed November 2024.

Share on: